CEMP : Summary for Cempra, Inc. - Yahoo Finance

U.S. Markets closed

Cempra, Inc. (CEMP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.90-0.30 (-7.14%)
At close: 4:00PM EDT

3.90 0.00 (0.00%)
After hours: 5:35PM EDT

People also watch
TTPHESPRCLVSFOLDPTLA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.20
Open4.05
Bid3.85 x 1100
Ask3.95 x 1100
Day's Range3.85 - 4.18
52 Week Range2.55 - 26.95
Volume2,053,767
Avg. Volume2,708,836
Market Cap204.33M
Beta1.01
PE Ratio (TTM)-1.66
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 hours ago

    Cempra to Present at the 16th Annual Needham & Company Healthcare Conference

    CHAPEL HILL, N.C., March 29, 2017-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical ...

  • Investopediayesterday

    Cempra Withdraws Solithromycin MAA in Europe

    Cempra stock tumbles as it withdraws the marketing application for pneumonia drug in the EU.

  • American City Business Journalsyesterday

    For Chapel Hill's Cempra, no European launch for now

    Amid a 67 percent workforce reduction following the U.S. Food and Drug Administration’s rejection of its pneumonia drug, solithromycin, Chapel Hill-based Cempra (CEMP) is pulling back on its plans to launch the drug in Europe. The company announced Tuesday that it has withdrawn its marketing authorization application (MAA) aimed at approval from the European Medicines Agency (EMA) for the drug to treat community-acquired pneumonia in adult patients. “We believe the most efficient path to approval is to withdraw the MAA at this time and to resubmit it with the additional data requested by the FDA,” said David Zaccardelli, acting chief executive officer of Cempra, in a statement.